Skip to main content
Clinical Trials/NCT03144960
NCT03144960UnknownNot Applicable

Mechanical Thrombectomy Of Acute Occlusion In Ischemic Stroke

Assiut University0 sites20 target enrollmentStarted: November 2017Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
20
Primary Endpoint
Treatment Of Acute Occlusion In Ischemic Stroke by Mechanical Thrombectomy

Study Overview

Brief Summary

Assessment of Therapeutic benefits and hazards of Mechanical Thrombectomy in Ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset.

Detailed Description

Stroke is an acute neurologic dysfunction of vascular origin with sudden or at least rapid occurrence of symptoms and signs corresponding to the involvement of focal areas in the brain.The two main types of stroke are ischemic and hemorrhagic.Thrombosis can form in the extracranial and intracranial arteries when the intima is roughened and plaque forms along the injured vessel.The endothelial injury permits platelets to adhere and aggregate, then coagulation is activated and thrombus develops at site of plaque.Blood flow through the extracranial and intracranial systems decreases, and the collateral circulation maintains function. When the compensatory mechanism of collateral circulation fails, perfusion is compromised, leading to decreased perfusion and cell death. Stroke is the third leading cause of death in the United States. Many people die each year from stroke in the United States.Stroke is the leading cause of serious, long-term disability in the United States. Nearly one fourth of strokes occur in people under the age of 65.High blood pressure is the most important risk factor for stroke. Intravenous recombinant tissue-type plasminogen activator is the only Food and Drug Administration approved treatment for acute ischemic stroke. Mechanical thrombectomy improves clinical outcomes in patients with acute ischemic stroke caused by a large vessel occlusion.There is no apparent benefit of intravenous thrombolysis to patients with ischemic stroke undergoing mechanical thrombectomy. The study will be performed involving ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Aged between 18 - 80 years old of both sex.
  • Acute ischemic stroke due to proved large-artery occlusion.
  • Ineligibility for IV thrombolysis.
  • A timeframe of ≤ 4.5 hours between stroke onset and the start of mechanical thrombectomy.
  • The patients included in this series should have an NIHSS score of at least 10 or fluctuating symptoms.
  • ASPECTS of 6 or > 6
  • All patients will be undergoing CT/CT angiography before and after treatment

Exclusion Criteria

  • Age older than 80 years or less than 18
  • Cerebral haemorrhage.
  • Acute infarction > 1/3 of middle cerebral artery (MCA) territory on CT-scan.
  • A history of stroke in the last 6 weeks.
  • A time interval of > 4.5 hours.
  • laboratory evidence of coagulation abnormalities.
  • Known arteriovenous malformation , neoplasm or aneurysm.
  • Woman at child bearing age who has a positive pregnancy test

Outcomes

Primary Outcomes

Treatment Of Acute Occlusion In Ischemic Stroke by Mechanical Thrombectomy

Time Frame: 18 months

Treatment of ischemic stroke patients after 4.5 hours from stroke onset by endovascular intervention by using Mechanical Thrombectomy techniques and without using Recombinant tissue-type plasminogen Activator and non eligible patients for Thrombectomy will be excluded. The number of people will be participated into this study will be 20 aged 18 to 80 years old The patients will be undergoing NIHSS score , ASPECTS score The patients will be undergoing CT/CT angiography The patients will be undergoing mechanical thrombectomy Results will be collected and correlated with the prognosis of the outcomes

Secondary Outcomes

  • The patients will be undergoing NIHSS score(1 hour)
  • The patients will be undergoing CT/CT angiography(2 hours)
  • The patients will be undergoing ASPECTS score(1 hour)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

AHMohamed

Dr

Assiut University

Similar Trials